Polyrizon Announces European Patent Publication for Trap & Target Nasal Drug Delivery Technology

Polyrizon Ltd. (Nasdaq: PLRZ), a development-stage biotech company specializing in intranasal hydrogels, announced on June 10, 2026, that the European Patent Office (EPO) has published its European patent application, EP 4751737. The application, titled “Mucoadhesive Polymers for Nasal Drug Delivery,” covers the company’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform. This platform is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention and improving drug absorption for more efficient delivery of active pharmaceutical ingredients. The publication is a key milestone in Polyrizon's strategy to strengthen its intellectual property portfolio and support future collaborations in the nasal drug delivery market. While the application is currently undergoing the European examination process, a granted patent would provide protection across multiple European markets, facilitating the company’s commercialization and partnering efforts. Polyrizon is also developing its Capture and Contain™ (C&C) technology, which acts as a biological mask against viruses and allergens.